主要从事肝脏疾病的发病机制及药物干预研究，重点聚焦药源性肝损伤（DILI）、代谢功能障碍相关脂肪性肝病（MASLD/MASH）、酒精性肝炎（AH）等疾病的病理分子机制解析及创新药物开发。主持国家自然科学基金、湖北省自然科学基金、武汉市知识创新专项等科研项目，并作为项目骨干参与“十四五”国家重点研发计划青年科学家项目等国家级重点课题。近年来以第一/通讯作者在Am J Pathol、Semin Liver Dis、J Nutr Biochem、Food Chem Toxicol、Mol Nutr Food Res等国际期刊发表SCI论文20余篇（H指数17）。已获授权实用新型专利5项。现任中华中医药学会中药毒理与安全性研究分会青年委员，同时担任Traditional Medicine Research、《中国临床药学杂志》等期刊的编委或青年编委。Am J Pathol、Carbohydr Polym、J Agric Food Chem、J Transl Med等期刊审稿人。
国家自然科学基金，青年科学基金项目，81903901，当归多糖靶向肝脏激活AMPK/SIRT1正反馈环路促进自噬治疗非酒精性脂肪肝病的机制研究，2020/01-2022/12，21万元，已结题，主持
湖北省自然科学基金，面上项目，2023AFB800，木犀草素重编程LOX介导的氧化脂质代谢治疗NASH的机制研究，2023/08-2025/08，5万元，在研，主持
武汉市知识创新专项项目，曙光计划，2022020801020467，基于计算机反向分子对接和靶向代谢组学技术探讨木犀草素治疗非酒精性脂肪性肝炎的作用机制，2022/06-2024/06，10万元，在研，主持
2023年度武当特色中药研究湖北省重点实验室开放课题，重点项目，WDCM2023003，木犀草素调控肝细胞铁死亡改善NASH的机制研究，2023/08-2025/08，2万元，在研，主持
2022年度生物靶向湖北省重点实验室开放基金，2022swbx015，木犀草素特异性抑制脂氧合酶（ALOX）12治疗非酒精性脂肪肝的分子机制研究，2022/12-2024/12，1万元，在研，主持
永利官网附属协和医院科学研究基金-自由创新预研基金，000004826，基于调控AMPK的当归多糖治疗NAFLD的作用及机制研究，2018/01-2019/12，5万元，已结题，主持
国家重点研发计划，十四五重点研发青年科学家项目，2022YFA1305600，肠道菌群失衡调控酒精相关肝病进展的机制研究和靶向精准调控，2022/12-2027/11，500万，在研，参与（项目骨干）
国家重点研发计划，2023YFF1205000，基于标靶组学的复方用药AI药效评估与智能推荐系统的开发与应用，2023/11-2026/10，609.5万，在研，参与（项目骨干）
国家自然科学基金面上项目，82270614，Let-7b-5p-Adrb3轴调控线粒体稳态在NAFLD脂肪代谢重塑中的作用及机制，2023/01-2026/12，50万元，在研，参与
Cao P（曹鹏）, Jaeschke H, Ni HM, Ding WX. The Ways to Die: Cell Death in Liver Pathophysiology.Semin Liver Dis. 2025Apr 28. doi: 10.1055/a-2576-4332. Epub ahead of print. PMID: 40199509.
Cao P（曹鹏）, Chao X, Ni HM, Ding WX. An Update on Animal Models of Alcohol-Associated Liver Disease.Am J Pathol. 2025Jan 28:S0002-9440(25)00032-X. doi: 10.1016/j.ajpath.2024.11.011. Epub ahead of print. PMID: 39884572.
Peng Cao（曹鹏）,Yu Zhang, Zi Huang, Mitchell A. Sullivan, Zihao He, Jinglin Wang, Zehong Chen, Huiping Hu, Kaiping Wang*.The Preventative Effects of Procyanidin on Binge Ethanol‐Induced Lipid Accumulation and ROS Overproduction Via the Promotion of Hepatic Autophagy.MolecularNutrition & Food Research.2019Sep;63(18):e1801255.(封面文章,中科院2区，IF=5.309)
Peng Cao（曹鹏，共同通讯作者）#,*, Yi Wang#, Cong Zhang#, Mitchell A. Sullivan, Wen Chen, Xiang Jing, Huifan Yu, Fei Li,Qu Wang, Zhongshi Zhou, Qi Wang, Wen Tian, Zhenpeng Qiu*, Lianxiang Luo*. Quercetin ameliorates non-alcoholic fatty liver disease (NAFLD) via the promotion of AMPK-mediated hepatic autophagy.The Journal of Nutritional Biochemistry.2023Jul 7;120:109414.(中科院2区，IF 5.6)
Peng Cao（曹鹏）#, Jun Gan#, Sanlan Wu#, Yixin Hu, Bin Xia, Xiaoyue Li, Hongan Zeng, Bingyu Cheng, Huifan Yu, Fei Li, Luqin Si*, Jiangeng Huang*. Molecular mechanisms of hepatoprotective effect of tectorigenin against ANIT-induced cholestatic liver injury: Role of FXR and Nrf2 pathways.Food Chem Toxicol.2023Jun 20;178:113914.(中科院2区，IF 4.3)
Peng Cao（曹鹏）#, Yue Wu#, Yaping Li#, Liping Xiang, Bingyu Cheng, Yixin Hu, Xin Jiang, Zhe Wang, Sanlan Wu, Luqin Si, Qiang Yang, Jian Xu*, Jiangeng Huang*.The important role of glycerophospholipid metabolism in the protective effects of polyphenols-enriched Tartary buckwheat extract against alcoholic liver disease.Food & Function.2022Oct 17;13(20):10415-10425.(中科院1区，IF 6.317)
Li Y, Qi P, Song SY, Wang Y, Wang H,Cao P*（曹鹏，共同通讯作者）, Liu Y*, Wang Y*. Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease.Biomed Pharmacother. 2024 May;174:116585.(中科院2区，IF6.90)
Peng Cao（曹鹏）, Jinlu Sun, Mitchell A Sullivan, Xiao Huang, Hanxiang Wang, Yu Zhang, Na Wang, Kaiping Wang*. Angelica sinensis polysaccharide protects against acetaminophen-induced acute liver injury and cell death by suppressing oxidative stress and hepatic apoptosis in vivo and in vitro.Int J Biol Macromol.2018May;111:1133-1139.(中科院1区，IF 8.025)
Peng Cao（曹鹏，共同通讯作者）*, Wu S, Wu T, Deng Y, Zhang Q, Wang K, Zhang Y*. The important role of polysaccharides from a traditional Chinese medicine-Lung Cleansing and Detoxifying Decoction against the COVID-19 pandemic.Carbohydr Polym.2020Jul 15;240:116346.(中科院1区，IF 10.723)
Peng Cao（曹鹏，共同通讯作者）#,*, Ming Yue#, Yuanlei Cheng#, Mitchell A. Sullivan, Wen Chen, Huifan Yu, Fei Li, Sanlan Wu, Yongning Lv, Xuejia Zhai*, Yu Zhang*. Naringenin prevents non-alcoholic steatohepatitis by modulating the host metabolome and intestinal microbiome in MCD diet-fed mice.Food Science & Nutrition.2023Sep 27;11(12):7826-7840.(中科院2区，IF 3.9)
Lu Y#, Zhang C#, Song Y, Chen L, Chen X, Zheng G, Yang Y,Cao P*（曹鹏，共同通讯作者）, Qiu Z*. Gallic acid impairs fructose-driven de novo lipogenesis and ameliorates hepatic steatosis via AMPK-dependent suppression of SREBP-1/ACC/FASN cascade.Eur J Pharmacol.2023Feb 5:940:175457.(中科院2区，IF 5.195)
Quancheng Yang#,Peng Cao（曹鹏，共同一作）#, Yi Lv, Hua Peng*, Xuejia Zhai*. Development and validation of a sensitive and simple LC-MS/MS method for simultaneous quantitation of valsartan, sacubitril and sacubitrilat in pediatric population.J Pharm Biomed Anal.2024Jan 20:238:115829.(中科院2区，IF 3.4)
Wei Guo#, Lian Xiang Luo#, Yan Meng#, Wen Chen, Lixiu Yu, Cong Zhang, Zhenpeng Qiu*,Peng Cao（曹鹏，通讯作者）*. Luteolin alleviates methionine-choline deficient diet-induced non-alcoholic steatohepatitis by modulating host serum metabolome and gut microbiome.Front. Nutr.2022Jul 28;9:936237.(中科院2区，IF 6.590)
Jingtong Qin#,Peng Cao（曹鹏，共同一作）#, Xuexuan, Zeyao Zeng, Liyan Deng, Lianxiang Luo*. Machine learning identifies ferroptosis-related gene ANXA2 as potential diagnostic biomarkers for NAFLD.Front Endocrinol (Lausanne). 2023Dec 19;14:1303426.(中科院2区，IF 5.2)
Yinglin Liao#, Peng Cao（曹鹏，共同一作）#, Lianxiang Luo *.Identification of novel ALOX15 inhibitors based on Bayesian classifier model and computer-aided high-throughput virtual screening.Pharmaceuticals.2022, 15, 1440.(中科院3区，IF 5.215)
Fei Xiong, Qiao Zhou, Xiaobo Huang, Peng Cao（曹鹏，共同通讯作者）*,Yi Wang*. Ferroptosis Plays a Novel Role in Nonalcoholic Steatohepatitis Pathogenesis.Front Pharmacol.2022 Dec 2;13:1055793.(中科院2区，IF 5.988)
Peng Cao（曹鹏）#,Wei Guo#,Jun Wang#,Sanlan Wu,Yifei Huang,Yang Wang*,Yani Liu*, Yu Zhang*. Population pharmacokinetic study of pemetrexed in Chinese primary advanced non-small cell lung carcinoma patients.Front Pharmacol.2022Aug 25;13:954242.(中科院2区，IF 5.988)
Yuzhen Lu, Junjie Hu, Liang Chen, Shan Li, Ming Yuan, Xianxiang Tian*,Peng Cao（曹鹏，共同通讯作者）*, Zhenpeng Qiu*.Ferroptosis as an Emerging Therapeutic Target in Liver Diseases.Front Pharmacol.2023May 15;14:1196287.(中科院2区，IF 5.988)
Peng Cao（曹鹏，共同一作）#, Yongyi Liang#, Yi Wang#, Chao Mao, Weijia Wang, Sha Li, Lianxiang Luo*.Editorial: Liver diseases and programmed cell death.Front Pharmacol.2023Mar 28;14:1182013.(中科院2区，IF 5.988)
Wei-Jing Gong#,Peng Cao（曹鹏，共同一作）#, Qi-Lin Zhang, Xiao-Yu Han, Shuo-Wen Wang, Yi-Fei Huang, San-Lan Wu, Qiang Li, Rui Zhang, Shuang-Bing Xu, Ya-Ni Liu, Shao-Jun Shi, Yu Zhang*. Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling.Translational Oncology.2022May;19:101393. (中科院2区，IF 5.0)
Peng Cao（曹鹏）#, Sanlan Wu#, Wei Guo, Qilin Zhang, Weijing Gong, Qiang Li, Rui Zhang, Xiaorong Dong, Shuangbing Xu, Yani Liu, Shaojun Shi, Yifei Huang*, Yu Zhang*. Precise pathological classification of non-small cell lung adenocarcinoma and squamous carcinoma based on an integrated platform of targeted metabolome and lipidome.Metabolomics.2021Nov 3;17(11):98.(中科院3区，IF 4.747)
Peng Cao（曹鹏）#, Wu Y#, Wu S, Wu T, Zhang Q, Zhang R, Wang Z, Zhang Y*. Elevated serum ferritin level effectively discriminates severity illness and liver injury of coronavirus disease 2019 pneumonia.Biomarkers.2021May;26(3):207-212.(中科院4区，IF 2.663)
Peng Cao（曹鹏）, Gao Li, Ling Huang, Shouwei Zhao, Yang Hu, Lixia Qin, Lihui Qiu, Wenwen Zhu, Luqin Si, Jiangeng Huang*. Screening of stabilizers for LC–MS/MS analysis of clevidipine and its primary metabolite in dog whole blood.Bioanalysis.2015, 7(12), 1457–1469. (中科院3区，IF 2.695)
曹鹏,伍三兰,张琪琳,龚卫静,黄怡菲,张玉*. LC-MS/MS法联合ICP-MS法测定非小细胞肺癌患者血浆培美曲塞及顺铂的浓度[J].中国医院药学杂志,2022,42(12):1181-1185.
曹鹏,张玉,汪汉香,张琪林,李强,王凯平*.当归多糖对小鼠急性酒精性肝损伤的预防作用及对HIF-1α蛋白的影响.中华中医药杂志.2021,36(06):3628-3631.
曹鹏;伍三兰;吴婷婷;张琪琳;于丽秀;一种婴幼儿皮肤贴,2021-07-02,中国,ZL202022074697. 0，CN202022074697.0
张玉;刘亚妮;伍三兰;黄怡菲;曹鹏;龚卫静;师少军;胡艳珂;李强;张蕊;杨玉;徐双兵;董晓荣;伍钢;培美曲塞化疗后不良反应发生风险预测模型及其构建方法, 2023-8-29,中国, ZL 2021 10229968.1
